Admera Health

Executive Summary

Admera Health is a private diagnostics company headquartered in South Plainfield, New Jersey, offering a comprehensive suite of genomic and bioinformatic services to academic, biotech, biopharma, and pharmaceutical researchers. Its portfolio includes RNA-seq, single-cell RNA-seq, spatial transcriptomics, whole-genome sequencing (WGS), whole-exome sequencing (WES), methyl-seq, and more. Founded in 2012, the company positions itself as a key enabler in precision medicine by providing high-quality, scalable genomics solutions that support drug discovery, biomarker development, and translational research. As demand for multiomics and spatial biology accelerates, Admera Health is well-placed to capture growth, though its private status and lack of disclosed financials limit visibility into near-term performance. The company's focus on research services rather than clinical diagnostics suggests a steady, contract-driven revenue model with opportunities for expansion into regulated testing and strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-20 pharmaceutical company for drug discovery services40% success
• Q2 2026Launch of single-cell multiomics service (e.g., incorporating proteomics or ATAC-seq)60% success
• Q3 2026Expansion into clinical diagnostics through CLIA certification and test development30% success